Remove 2024 Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

AIPAC launches inaugural programme for MSMEs in pharma sector

Express Pharma

The All India Pharmaceutical Associations Consortium (AIPAC) launched its first programme for Micro, Small, and Medium Enterprises (MSMEs) in the pharmaceutical sector on 12 December 2024. It was designed to enhance the skills of pharmaceutical professionals and promote scientific excellence. The programme was led by S.

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Asahi Kasei establishes life science division to streamline bioprocess operations for pharma sector

Express Pharma

In 2023, the company enhanced its Glenview, Illinois facility to meet the rising market need for fluid management systems and virus filtration technologies. In 2024, it completed a new Planova assembly plant in Nobeoka, Miyazaki, Japan, to ensure consistent global supply.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database. ASOs accounted for more than half ($3.54

article thumbnail

EY Parthenon – OPPI report claims India’s pharma sector set for rapid growth

Express Pharma

Between September and October 2024, EY-P and OPPI undertook primary research * consulting top CXOs from leading Indian and global multinational pharmaceutical companies, to understand their perspective on the pivotal growth areas for the Indian pharma industry. There should be transparency in all reporting.

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. billion.

article thumbnail

Pharmaceutical Technology Excellence Awards 2025: i3 Membrane

Pharmaceutical Technology

This rapid processing not only enhances throughput, but will also allow pharmaceutical companies to respond more swiftly to market demands. This flexibility is particularly beneficial for pharmaceutical manufacturers looking to upgrade their research and discovery processes without overhauling their entire systems.